ClinicalTrials.gg
CompletedNCT03744468Updated Apr 2, 2026Results posted

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

A Phase 1/2 interventional study of Surzebiclimab and Tislelizumab in Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion and NSCLC for Phase 2 Dose Expansion, sponsored by BeiGene. Completed at 40 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
147
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 13 under way, none of them phase 3. tislelizumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
3rd of 16
147 · median 41
Started
2018
the only one that year
Phase 1/2
3 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
1 of 16
BeiGene

Among the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 1st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.

Read the detailed description

Blocking antibodies targeting programmed cell death protein-1 (PD-1) have achieved remarkable results in the treatment of many types of tumors. However, based upon the rate of primary and secondary resistance to PD-1 blockade, it was apparent that additional immuno-regulatory mechanism(s) underlie tumor immune escape. Indeed, research shows that the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) pathway cooperates with PD-1 to maximize the suppression of effector tumor infiltrating lymphocytes (TILs) as well as promote resistance to anti-PD-1 therapy. Therefore, TIM-3 represents an ideal target with the potential to significantly improve and/or extend the therapeutic benefit of anti-PD-1 therapy to a greater number of participants.

TIM-3, Lymphocyte activation gene-3 (LAG-3), and PD-1 function as immune checkpoint receptors in the overlapping regulation of immune tolerance and have been shown to be co-overexpressed on the TILs from the participant samples of various solid tumors. Furthermore, emerging clinical data and preclinical data demonstrate co-expression of TIM-3, LAG-3, PD-1 often yield T cells exhausted immunophenotype (i.e., cytokine expression, proliferation etc.). Cancer cells take advantage of PD-1, TIM-3, and LAG-3 in inhibiting immune cells' function, and escape the immune surveillance. Based upon the overlapping expression profiles and immuno-regulatory functions, TIM-3 and LAG-3 mediated adaptive resistance, there was strong scientific rationale that simultaneous targeting of these checkpoint blockers, could potentially increase therapeutic benefit and might help to overcome the resistance arising due to anti-PD-(L)-1 therapy. Hence, this study evaluated the safety and preliminary efficacy of surzebiclimab (anti TIM-3), alcestobart (Anti-LAG-3) in combination with tislelizumab (anti PD-1) in patients with advanced solid tumors.

This was an open-label, multicenter, nonrandomized Phase 1 and Phase 2 clinical trial. Phase 1 determined the recommended phase 2 dose (RP2D) for the combination of surzebiclimab and tislelizumab. Phase 2 safety lead-in determined the RP2D for the combination of surzebiclimab, tislelizumab and/or alcestobart. Phase 2 dose expansion continued to evaluate the safety but also focus on the efficacy of the doublet or triplet treatment combination in select tumor types.

03

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
  • HNSCC for Phase 2 Dose Expansion
  • NSCLC for Phase 2 Dose Expansion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants were aged >=18 years.
  • Adequate organ function.
  • (ECOG) performance status \<=1.
  • Must have been able to provide a recently obtained or fresh tumor biopsy.
  • The phase 1 dose escalation and phase 2 safety lead-in enrolled participants with histologically/ confirmed advanced/ solid tumors who had previously received standard systemic therapy per local guidelines, unless it was not available, not tolerated or determined not appropriate based on investigators judgement, and had at least 1 evaluable lesion per (RECIST) v1.1.
  • The phase 2 dose expansion enrolled participants with recurrent/metastatic HNSCC (Cohorts 1 and 4) and advanced/metastatic NSCLC (Cohorts 2 and 5), with disease progression that occurred >=10 weeks from the initiation of /PD-L1 treatment for locally advanced or metastatic disease and had at least 1 outside of the central nervous system per RECIST v1.1.

Key Exclusion Criteria:

  • A history of severe reactions to other monoclonal antibodies.
  • Active disease or a history of autoimmune diseases that might relapse or a history of life-threatening toxicity related to prior immune therapy.
  • Any condition that required systemic treatment with either or other medication \<=14 days before administration of study drug.
  • A history of interstitial lung disease, noninfectious pneumonitis or uncontrolled lung diseases.
  • Prior therapy targeting TIM-3 and/or LAG-3.
  • The phase 2 dose expansion NSCLC cohorts excluded participants with known sensitizing epidermal growth factor receptor (EGFR) mutation, v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation, anaplastic lymphoma kinase (ALK) fusion, or c-ros oncogene 1 (ROS1) fusion.

NOTE: Other protocol defined Inclusion/Exclusion criteria might apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 2 Milligrams (mg) + Tislelizumab

    Participants received surzebiclimab 2 mg intravenous (IV) infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 2 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab

    Participants received surzebiclimab 6 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 6 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab

    Participants received surzebiclimab 20 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 20 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab

    Participants received surzebiclimab 60 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 60 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab

    Participants received surzebiclimab 200 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 200 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab

    Participants received surzebiclimab 400 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 400 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter, until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab

    Participants received surzebiclimab 800 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 800 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab

    Participants received surzebiclimab 1600 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 400 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 60 mg

    Participants received one dose of surzebiclimab 60 mg IV infusion on Day 1 of Cycle 1 and discontinued the study treatment. Cycle 1 consisted of 28 days.

    Drug: Surzebiclimab

  • Experimental
    Phase 1 (Dose Escalation): Surzebiclimab 1600 mg

    Participants received one dose of surzebiclimab 1600 mg IV infusion on Day 1 of Cycle 1 and discontinued the study treatment. Cycle 1 consisted of 28 days.

    Drug: Surzebiclimab

  • Experimental
    Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab

    Participants received alcestobart 300 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab

    Participants received alcestobart 600 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab

    Participants received alcestobart 1200 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + BGB-A425 + Tislelizumab

    Participants received alcestobart 300 mg IV infusion on day 1 of each cycle along with surzebiclimab 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab

    Participants received alcestobart 600 mg IV infusion on day 1 of each cycle along with surzebiclimab 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab

    Participants received alcestobart 900 mg IV infusion on day 1 of each cycle along with surzebiclimab 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab

    Participants with head and neck squamous cell carcinoma (HNSCC) received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab

    Participants with non-small cell lung cancer (NSCLC) received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab

  • Experimental
    Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab

    Participants with HNSCC received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with alcestobart 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab

    Participants with NSCLC received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with alcestobart 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.

    Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart

Interventions

  • DrugSurzebiclimab

    Humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody against TIM-3

    Also known as: BGB-A425

  • Humanized, IgG4-variant monoclonal antibody against PD-1

    Also known as: BGB-A317

  • Human anti LAG-3 antibody

    Also known as: LBL-007

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.

    Time frame: Up to 30 days after last dose of study drug (maximum treatment duration: up to 32.7 months)

  2. Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab

    The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 1, therefore the MAD was reported.

    Time frame: Up to 28 days

  3. Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab

    The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.

    Time frame: Up to 28 days

  4. Phase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEs

    An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.

    Time frame: Up to 30 days after last dose of study drug (maximum duration of treatment: up to 19.6 months in Cohort A and up to 21.5 months in Cohort B)

  5. Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab

    The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.

    Time frame: Up to 21 days

  6. Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab

    The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.

    Time frame: Up to 21 days

  7. Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab

    The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.

    Time frame: Up to 21 days

  8. Phase 2 (Dose Expansion): Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who had complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to11.3 months, Cohort 5: up to 15.9 months

Secondary outcomes

  1. Phase 1: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Maximum time on study: up to 57.5 months

  2. Phase 2 (Safety Lead- In): Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months

  3. Phase 1: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a best overall response (BOR) of CR, PR, or stable disease (SD), per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

    Time frame: Maximum time on study: up to 57.5 months

  4. Phase 2 (Safety Lead-In): Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months

  5. Phase 2 (Dose Expansion): Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months

  6. Phase 2 (Dose Expansion): Duration of Response (DOR)

    DOR was defined as the time from the first determination of an overall response per RECIST v1.1 until the first documentation of progression or death, whichever came first. DOR was estimated using the Kaplan-Meier method. Per RECIST v.1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From the first determination of an overall response until PD or death, whichever came first (Maximum time on study [Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months])

  7. Phase 2 (Dose Expansion): Progression Free Survival (PFS)

    Progression free survival was defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of disease progression assessed by investigator or death, whichever occurred first as determined from investigator derived tumor assessments per RECIST 1.1. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months

  8. Phase 1: Maximum Observed Plasma Concentration (Cmax) of Surzebiclimab

    The maximum observed plasma concentration of surzebiclimab was measured in Cycle 1 and Cycle 5.

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI; within 30 minutes), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI. Cycle 1 was 28 days and Cycle 5 was 21 days.

  9. Phase 2 (Dose Expansion): Cmax of Surzebiclimab

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  10. Phase 1: Minimum Observed Plasma Concentration (Cmin) of Surzebiclimab

    Cmin of surzebiclimab was determined.

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI (Cycle 1 was 28 days; Cycle 2 and thereafter were 21 days)

  11. Phase 2 (Dose Expansion): Cmin of Surzebiclimab

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI

  12. Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Surzebiclimab

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI (Cycle 1 was28 days; Cycle 2 and thereafter were 21 days)

  13. Phase 2 (Dose Expansion): Tmax of Surzebiclimab

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  14. Phase 1: Half-Life (t1/2) of Surzebiclimab

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)

  15. Phase 2 (Dose Expansion): T1/2 of Surzebiclimab

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  16. Phase 1: Area Under Curve From 0 to 21 Days (AUC0-21d) of Surzebiclimab

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (Cycle 1 was 28 days; Cycle 2 and thereafter were 21 days)

  17. Phase 2 (Dose Expansion): AUC0-21d of Surzebiclimab

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle duration= 21 days)

  18. Phase 1: Clearance (CL/F) of Surzebiclimab

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)

  19. Phase 2 (Dose Expansion): CL/F of Surzebiclimab

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI

  20. Phase 1: Volume of Distribution (Vz/F) of Surzebiclimab

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)

  21. Phase 2 (Dose Expansion): Vz/F of Surzebiclimab

    Vz/F of surzebiclimab was determined.

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI

  22. Phase 2 (Safety Lead-In): Cmax of Alcestobart

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  23. Phase 2 (Safety Lead-In): Cmin of Alcestobart

    Cmin of alcestobart was determined.

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  24. Phase 2 (Safety Lead-In): Tmax of Alcestobart

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  25. Phase 2 (Safety Lead-In): t1/2 of Alcestobart

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  26. Phase 2 (Safety Lead-In): AUC0-21d of Alcestobart

    Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)

  27. Phase 2 (Safety Lead-In): CL/F of Alcestobart

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI

  28. Phase 2 (Safety Lead-In): Vz/F of Alcestobart

    Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI

  29. Phase 1: Serum Concentrations of Tislelizumab

    Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).

    Time frame: Pre-dose and EOI (within 30 minutes) on Cycle 1 Day 8 and Cycle 5 Day 1, and pre-dose on Day 1 of Cycles 2, 3, 6, 9, 13, 17, and 25 (Cycle 1 was 28 days, Cycle 2 and thereafter were 21 days)

  30. Phase 2 (Dose Expansion): Serum Concentrations of Tislelizumab

    Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 5, 6, 9, 13, 17, 25 and at EOI (within 30 minutes) on Day 1 of Cycles 1 and 5 (each cycle was 21 days)

  31. Phase 1: Number of Participants With Anti-Drug Antibodies (ADA) to Surzebiclimab

    Immunogenic responses to surzebiclimab included: treatment emergent, treatment-induced and treatment boosted anti-drug antibodies (ADA) and neutralizing antibody (NAb) positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the Baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive Nab at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: up to 57.5 months

  32. Phase 2 (Safety Lead-In) Cohort B: Number of Participants With Anti-Drug Antibodies to Surzebiclimab

    Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study in Cohort B: up to 21.5 months

  33. Phase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Surzebiclimab

    Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months

  34. Phase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Alcestobart

    Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months

  35. Phase 2 (Dose Expansion) Cohorts 4 and 5: Number of Participants With Anti-Drug Antibodies to Alcestobart

    Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months

  36. Phase 1: Number of Participants With Anti-Drug Antibodies to Tislelizumab

    Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: up to 57.5 months

  37. Phase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Tislelizumab

    Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months

  38. Phase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Tislelizumab

    Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

    Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months

  39. Phase 2 (Dose Expansion): Number of Participants With TEAEs and SAEs

    An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.

    Time frame: Up to 30 days after last dose of study drug (maximum treatment duration: Cohort 1: up to 6.9 months, Cohort 2: up to 23.5 months, Cohort 4: up to 9.6 months, Cohort 5: up to 15.4 months)

07

Results

Posted Apr 2, 2026
Limitations and caveats
Based on the interim analysis of Cohorts 1, 2, 4, 5 in dose expansion, sponsor decided not to further investigate the combinations in RCC and to not investigate alcestobart (LBL-007), double or triple treatment combination in PD-1 resistant NSCLC and HNSCC. Hence, Phase 2 (Dose Expansion) Cohorts 3, 6 and 7 were planned, but not initiated based on sponsor's decision.

Participant flow

Participant flow — Overall Study
MilestonePhase 1 (Dose Escalation): Surzebiclimab 2 Milligrams (mg) + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + BGB-A425 + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Started113574731146636621222020
Completed00215242000000000000
Not completed111422311146636621222020
Withdrew: Death11011211102320341511118
Withdrew: Lost to follow-up00021010010010000000
Withdrew: Physician decision00100000000001000000
Withdrew: Sponsor decision00000010000000000000
Withdrew: Withdrawal by subject00010000000120004821
Withdrew: Other000000000022123223711

Outcome measures

PrimaryPhase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.

Time frame:
Up to 30 days after last dose of study drug (maximum treatment duration: up to 32.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Any TEAE1135747311
Grade 3 or above TEAE1022335111
Serious TEAE1132321011
PrimaryPhase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab

The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 1, therefore the MAD was reported.

Time frame:
Up to 28 days
Reported as:
Number · milligram (mg)
Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab
milligram (mg)Phase 1 (Dose Escalation): Surzebiclimab + Tislelizumab
Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab1600
PrimaryPhase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab

The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.

Time frame:
Up to 28 days
Reported as:
Number · milligram (mg)
Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab
milligram (mg)Phase 1 (Dose Escalation): Surzebiclimab + Tislelizumab
Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab600
PrimaryPhase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEs

An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.

Time frame:
Up to 30 days after last dose of study drug (maximum duration of treatment: up to 19.6 months in Cohort A and up to 21.5 months in Cohort B)
Reported as:
Count of participants · Participants
Phase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEs
ParticipantsPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Any TEAE466356
Grade 3 or above TEAE334154
Serious AE334143
PrimaryPhase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab

The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.

Time frame:
Up to 21 days
Reported as:
Number · milligram (mg)
Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab
milligram (mg)Phase 2 (Safety Lead-In): Alcestobart + Tislelizumab
Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab1200
PrimaryPhase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab

The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.

Time frame:
Up to 21 days
Reported as:
Number · milligram (mg)
Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab
milligram (mg)Phase 2 (Safety Lead-In): Alcestobart + Surzebiclimab + Tislelizumab
Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab900
PrimaryPhase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab

The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.

Time frame:
Up to 21 days
Reported as:
Number · milligram (mg)
Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab
milligram (mg)Phase 2 (Safety Lead-In): Alcestobart + Surzebiclimab + Tislelizumab
Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab600
PrimaryPhase 2 (Dose Expansion): Overall Response Rate (ORR)

ORR was defined as the percentage of participants who had complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to11.3 months, Cohort 5: up to 15.9 months
Reported as:
Number · percentage of participants
Phase 2 (Dose Expansion): Overall Response Rate (ORR)
percentage of participantsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Phase 2 (Dose Expansion): Overall Response Rate (ORR)4.8 (0.1 to 23.8)9.1 (1.1 to 29.2)0.0 (0.0 to 16.8)10.5 (1.3 to 33.1)
SecondaryPhase 1: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Maximum time on study: up to 57.5 months
Reported as:
Number · percentage of participants
Phase 1: Overall Response Rate (ORR)
percentage of participantsPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Phase 1: Overall Response Rate (ORR)0.0 (0.0 to 97.5)0.0 (0.0 to 97.5)0.0 (0.0 to 70.8)0.0 (0.0 to 52.2)0.0 (0.0 to 45.9)25.0 (0.6 to 80.6)14.3 (0.4 to 57.9)0.0 (0.0 to 70.8)0.0 (0.0 to 97.5)—
SecondaryPhase 2 (Safety Lead- In): Overall Response Rate (ORR)

ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Reported as:
Number · percentage of participants
Phase 2 (Safety Lead- In): Overall Response Rate (ORR)
percentage of participantsPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Phase 2 (Safety Lead- In): Overall Response Rate (ORR)0.0 (0.0 to 60.2)33.3 (4.3 to 77.7)0.0 (0.0 to 45.9)0.0 (0.0 to 70.8)0.0 (0.0 to 45.9)16.7 (0.4 to 64.1)
SecondaryPhase 1: Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a best overall response (BOR) of CR, PR, or stable disease (SD), per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Time frame:
Maximum time on study: up to 57.5 months
Reported as:
Number · percentage of participants
Phase 1: Disease Control Rate (DCR)
percentage of participantsPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Phase 1: Disease Control Rate (DCR)0.0 (0.0 to 97.5)0.0 (0.0 to 97.5)66.7 (9.4 to 99.2)40.0 (5.3 to 85.3)66.7 (22.3 to 95.7)50.0 (6.8 to 93.2)57.1 (18.4 to 90.1)66.7 (9.4 to 99.2)0.0 (0.0 to 97.5)—
SecondaryPhase 2 (Safety Lead-In): Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Reported as:
Number · percentage of participants
Phase 2 (Safety Lead-In): Disease Control Rate (DCR)
percentage of participantsPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Phase 2 (Safety Lead-In): Disease Control Rate (DCR)50.0 (6.8 to 93.2)83.3 (35.9 to 99.6)50.0 (11.8 to 88.2)100.0 (29.2 to 100.0)50.0 (11.8 to 88.2)50.0 (11.8 to 88.2)
SecondaryPhase 2 (Dose Expansion): Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Reported as:
Number · percentage of participants
Phase 2 (Dose Expansion): Disease Control Rate (DCR)
percentage of participantsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Phase 2 (Dose Expansion): Disease Control Rate (DCR)42.9 (21.8 to 66.0)45.5 (24.4 to 67.8)45.0 (23.1 to 68.5)73.7 (48.8 to 90.9)
SecondaryPhase 2 (Dose Expansion): Duration of Response (DOR)

DOR was defined as the time from the first determination of an overall response per RECIST v1.1 until the first documentation of progression or death, whichever came first. DOR was estimated using the Kaplan-Meier method. Per RECIST v.1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From the first determination of an overall response until PD or death, whichever came first (Maximum time on study [Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months])
Reported as:
Median · months
Phase 2 (Dose Expansion): Duration of Response (DOR)
monthsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Phase 2 (Dose Expansion): Duration of Response (DOR)4.06.9 (5.6 to NA)—NA (2.8 to NA)
SecondaryPhase 2 (Dose Expansion): Progression Free Survival (PFS)

Progression free survival was defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of disease progression assessed by investigator or death, whichever occurred first as determined from investigator derived tumor assessments per RECIST 1.1. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Reported as:
Median · months
Phase 2 (Dose Expansion): Progression Free Survival (PFS)
monthsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Phase 2 (Dose Expansion): Progression Free Survival (PFS)1.4 (1.4 to 2.6)1.7 (1.3 to 4.0)1.9 (1.2 to 2.8)4.0 (1.4 to 7.2)
SecondaryPhase 1: Maximum Observed Plasma Concentration (Cmax) of Surzebiclimab

The maximum observed plasma concentration of surzebiclimab was measured in Cycle 1 and Cycle 5.

Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI; within 30 minutes), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI. Cycle 1 was 28 days and Cycle 5 was 21 days.
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Surzebiclimab
micrograms per milliliter (mcg/mL)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Cycle 1 Day 1—0.895.48 ± 2417.43 ± 3866.50 ± 25145.09 ± 20244.03 ± 25604.10 ± 919.20534.00
Cycle 5 Day 1——6.96 ± 1726.62 ± 65123.87 ± 14222.86 ± 45470.02 ± 19885.00——
SecondaryPhase 2 (Dose Expansion): Cmax of Surzebiclimab
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Geometric mean · mcg/mL
Phase 2 (Dose Expansion): Cmax of Surzebiclimab
mcg/mLPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab
Cycle 1 Day 1182.24 ± 17165.62 ± 22
Cycle 5 Day 1—288.43 ± 31
SecondaryPhase 1: Minimum Observed Plasma Concentration (Cmin) of Surzebiclimab

Cmin of surzebiclimab was determined.

Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI (Cycle 1 was 28 days; Cycle 2 and thereafter were 21 days)
Reported as:
Geometric mean · mcg/mL
Phase 1: Minimum Observed Plasma Concentration (Cmin) of Surzebiclimab
mcg/mLPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Cycle 1 Day 1———1.80 ± 8014.55 ± 4927.84 ± 3962.46 ± 33167.44 ± 27——
Cycle 5 Day 1——0.476.38 ± 4654.06 ± 857.43 ± 117173.58 ± 19537.02——
SecondaryPhase 2 (Dose Expansion): Cmin of Surzebiclimab
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Reported as:
Geometric mean · mcg/mL
Phase 2 (Dose Expansion): Cmin of Surzebiclimab
mcg/mLPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab
Cycle 1 Day 140.24 ± 2632.27 ± 44
Cycle 5 Day 1116.0587.92 ± 51
SecondaryPhase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Surzebiclimab
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI (Cycle 1 was28 days; Cycle 2 and thereafter were 21 days)
Reported as:
Median · hours
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Surzebiclimab
hoursPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Cycle 1 Day 1—1.30 (1.3 to 1.3)1.33 (1.1 to 6.1)1.15 (1.0 to 1.2)1.20 (1.0 to 5.1)1.15 (1.0 to 5.2)1.10 (1.1 to 6.3)1.22 (1.2 to 6.6)5.021.58
Cycle 5 Day 1——2.93 (0.7 to 5.2)0.72 (0.7 to 0.8)0.57 (0.5 to 0.6)5.66 (4.7 to 6.6)0.92 (0.6 to 6.7)0.62——
SecondaryPhase 2 (Dose Expansion): Tmax of Surzebiclimab
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Median · hours
Phase 2 (Dose Expansion): Tmax of Surzebiclimab
hoursPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab
Cycle 1 Day 14.54 (4.1 to 5.0)4.00 (1.0 to 23.6)
Cycle 5 Day 1—2.78 (0.5 to 22.3)
SecondaryPhase 1: Half-Life (t1/2) of Surzebiclimab
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)
Reported as:
Median · hours
Phase 1: Half-Life (t1/2) of Surzebiclimab
hoursPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Phase 1: Half-Life (t1/2) of Surzebiclimab——122.20 (117.9 to 126.5)203.43 (139.2 to 246.1)276.06 (174.4 to 628.5)344.59 (338.2 to 674.2)356.26 (327.9 to 512.2)643.02—99.20
SecondaryPhase 2 (Dose Expansion): T1/2 of Surzebiclimab
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Median · hours
Phase 2 (Dose Expansion): T1/2 of Surzebiclimab
hoursPhase 2 (Dose Expansion): Cohort 1: HNSCC: BGB A425 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: BGB A425 600 mg + Tislelizumab
Phase 2 (Dose Expansion): T1/2 of Surzebiclimab325.65 (224.5 to 523.7)274.83 (216.5 to 462.6)
SecondaryPhase 1: Area Under Curve From 0 to 21 Days (AUC0-21d) of Surzebiclimab
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (Cycle 1 was 28 days; Cycle 2 and thereafter were 21 days)
Reported as:
Geometric mean · hours*mcg/mL
Phase 1: Area Under Curve From 0 to 21 Days (AUC0-21d) of Surzebiclimab
hours*mcg/mLPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Cycle 1 Day 1——727.11 ± 312734.25 ± 4412911.99 ± 3425213.19 ± 3050478.81 ± 25153224.06—70304.42
Cycle 5 Day 1——999.31 ± 365518.62 ± 2938776.66 ± 134857.77138368.71 ± 20303366.23——
SecondaryPhase 2 (Dose Expansion): AUC0-21d of Surzebiclimab
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle duration= 21 days)
Reported as:
Geometric mean · hours*mcg/mL
Phase 2 (Dose Expansion): AUC0-21d of Surzebiclimab
hours*mcg/mLPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab
Cycle 1 Day 137538.32 ± 1531104.68 ± 26
Cycle 5 Day 190437.8466659.54 ± 34
SecondaryPhase 1: Clearance (CL/F) of Surzebiclimab
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)
Reported as:
Geometric mean · Liters per hour (L/h)
Phase 1: Clearance (CL/F) of Surzebiclimab
Liters per hour (L/h)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Phase 1: Clearance (CL/F) of Surzebiclimab——0.03 ± 280.02 ± 500.01 ± 570.01 ± 420.01 ± 110.00—0.02
SecondaryPhase 2 (Dose Expansion): CL/F of Surzebiclimab
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Reported as:
Geometric mean · Liters per hour (L/h)
Phase 2 (Dose Expansion): CL/F of Surzebiclimab
Liters per hour (L/h)Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab
Phase 2 (Dose Expansion): CL/F of Surzebiclimab0.01 ± 210.01 ± 38
SecondaryPhase 1: Volume of Distribution (Vz/F) of Surzebiclimab
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)
Reported as:
Geometric mean · Liters (L)
Phase 1: Volume of Distribution (Vz/F) of Surzebiclimab
Liters (L)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mg
Phase 1: Volume of Distribution (Vz/F) of Surzebiclimab——4.43 ± 335.04 ± 374.48 ± 225.55 ± 305.56 ± 344.38—3.15
SecondaryPhase 2 (Dose Expansion): Vz/F of Surzebiclimab

Vz/F of surzebiclimab was determined.

Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Reported as:
Geometric mean · Liters (L)
Phase 2 (Dose Expansion): Vz/F of Surzebiclimab
Liters (L)Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab
Phase 2 (Dose Expansion): Vz/F of Surzebiclimab4.98 ± 335.69 ± 16
SecondaryPhase 2 (Safety Lead-In): Cmax of Alcestobart
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Geometric mean · mcg/mL
Phase 2 (Safety Lead-In): Cmax of Alcestobart
mcg/mLPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Cycle 1 Day 161.21 ± 51112.96 ± 24242.51 ± 1961.39 ± 32115.74 ± 25149.57 ± 28
Cycle 5 Day 157.60177.18 ± 15294.49 ± 1786.40139.24 ± 9245.81 ± 45
SecondaryPhase 2 (Safety Lead-In): Cmin of Alcestobart

Cmin of alcestobart was determined.

Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Geometric mean · mcg/mL
Phase 2 (Safety Lead-In): Cmin of Alcestobart
mcg/mLPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Cycle 1 Day 12.01 ± 30024.07 ± 4035.38 ± 279.32 ± 6212.81 ± 4326.44 ± 52
Cycle 5 Day 1—40.66 ± 3077.79 ± 1815.9532.55 ± 1467.12
SecondaryPhase 2 (Safety Lead-In): Tmax of Alcestobart
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Median · hours
Phase 2 (Safety Lead-In): Tmax of Alcestobart
hoursPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Cycle 1 Day 11.48 (1.2 to 1.8)2.84 (1.4 to 5.4)1.54 (1.2 to 6.0)1.42 (1.3 to 4.3)1.29 (1.2 to 6.1)1.28 (1.0 to 1.8)
Cycle 5 Day 10.834.57 (0.9 to 22.0)11.97 (0.6 to 23.4)0.674.18 (4.1 to 4.3)0.83 (0.7 to 1.0)
SecondaryPhase 2 (Safety Lead-In): t1/2 of Alcestobart
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Median · hours
Phase 2 (Safety Lead-In): t1/2 of Alcestobart
hoursPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Phase 2 (Safety Lead-In): t1/2 of Alcestobart143.35 (56.5 to 214.8)248.79 (195.6 to 380.4)227.76 (188.8 to 284.1)230.84 (167.5 to 234.5)200.74 (152.4 to 255.5)262.83 (152.7 to 333.7)
SecondaryPhase 2 (Safety Lead-In): AUC0-21d of Alcestobart
Time frame:
Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Reported as:
Geometric mean · hours*mcg/mL
Phase 2 (Safety Lead-In): AUC0-21d of Alcestobart
hours*mcg/mLPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Cycle 1 Day 18620.04 ± 3421120.06 ± 1541874.14 ± 2610947.98 ± 3518655.37 ± 2530906.45 ± 25
Cycle 5 Day 1—41698.19 ± 2067245.59 ± 2016445.0832044.03 ± 1249948.77 ± 54
SecondaryPhase 2 (Safety Lead-In): CL/F of Alcestobart
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Reported as:
Geometric mean · L/h
Phase 2 (Safety Lead-In): CL/F of Alcestobart
L/hPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + BGB-A425 + Tislelizumab
Phase 2 (Safety Lead-In): CL/F of Alcestobart0.03 ± 370.02 ± 310.02 ± 260.02 ± 400.03 ± 260.02 ± 36
SecondaryPhase 2 (Safety Lead-In): Vz/F of Alcestobart
Time frame:
Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Reported as:
Geometric mean · Liters
Phase 2 (Safety Lead-In): Vz/F of Alcestobart
LitersPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Phase 2 (Safety Lead-In): Vz/F of Alcestobart5.48 ± 777.83 ± 107.29 ± 316.40 ± 297.59 ± 267.81 ± 20
SecondaryPhase 1: Serum Concentrations of Tislelizumab

Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).

Time frame:
Pre-dose and EOI (within 30 minutes) on Cycle 1 Day 8 and Cycle 5 Day 1, and pre-dose on Day 1 of Cycles 2, 3, 6, 9, 13, 17, and 25 (Cycle 1 was 28 days, Cycle 2 and thereafter were 21 days)
Reported as:
Geometric mean · mcg/mL
Phase 1: Serum Concentrations of Tislelizumab
mcg/mLPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab
Cycle 1 Day 8: Pre-dose————0.68—2.70—
Cycle 1 Day 8: End of Infusion40.5051.1057.91 ± 2454.87 ± 4664.19 ± 2666.23 ± 2567.66 ± 2064.05 ± 15
Cycle 2 Day 1: Pre-dose12.2014.0028.29 ± 10817.31 ± 2417.75 ± 4415.93 ± 3716.68 ± 2618.71 ± 38
Cycle 3 Day 1: Pre-dose——27.6049.64 ± 20134.83 ± 7826.40 ± 7928.2035.90
Cycle 5 Day 1: Pre-dose——34.50 ± 7149.31 ± 1864.82 ± 438.24 ± 8144.59 ± 2255.20
Cycle 5 Day 1: End of Infusion——82.60110.68 ± 26122.85 ± 7116.81 ± 53100.66 ± 2592.90
Cycle 6 Day 1: Pre-dose——46.58 ± 4451.39 ± 3569.54 ± 233.54 ± 8741.83 ± 3158.10
Cycle 9 Day 1: Pre-dose——57.95 ± 6—70.9024.1045.14 ± 372.20
Cycle 13 Day 1: Pre-dose——90.00—51.90—46.28 ± 4—
Cycle 17 Day 1: Pre-dose——87.90———45.79 ± 3—
Cycle 25 Day 1: Pre-dose——103.00———43.04 ± 10—
SecondaryPhase 2 (Dose Expansion): Serum Concentrations of Tislelizumab

Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).

Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 5, 6, 9, 13, 17, 25 and at EOI (within 30 minutes) on Day 1 of Cycles 1 and 5 (each cycle was 21 days)
Reported as:
Geometric mean · mcg/mL
Phase 2 (Dose Expansion): Serum Concentrations of Tislelizumab
mcg/mLPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Cycle 1 Day 1: Pre-dose9.09 ± 13710.61 ± 59326.45 ± 12513.57 ± 187
Cycle 1 Day 1: EOI62.51 ± 3077.36 ± 3295.63 ± 6960.27 ± 30
Cycle 2 Day 1: Pre-dose20.35 ± 3923.46 ± 8425.92 ± 10319.76 ± 73
Cycle 5 Day 1: Pre-dose34.47 ± 6139.51 ± 3935.54 ± 8332.96 ± 43
Cycle 5 Day 1: EOI84.82 ± 20102.93 ± 18106.79 ± 7696.71 ± 75
Cycle 6 Day 1: Pre-dose28.12 ± 3741.92 ± 4733.02 ± 17832.56 ± 48
Cycle 9 Day 1: Pre-dose29.7045.83 ± 2871.2039.05 ± 33
Cycle 13 Day 1: Pre-dose—49.57 ± 4764.2034.88 ± 44
Cycle 17 Day 1: Pre-dose—37.68 ± 60—38.54 ± 31
Cycle 25 Day 1: Pre-dose—63.70——
SecondaryPhase 1: Number of Participants With Anti-Drug Antibodies (ADA) to Surzebiclimab

Immunogenic responses to surzebiclimab included: treatment emergent, treatment-induced and treatment boosted anti-drug antibodies (ADA) and neutralizing antibody (NAb) positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the Baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive Nab at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: up to 57.5 months
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Anti-Drug Antibodies (ADA) to Surzebiclimab
ParticipantsPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab
Treatment-Emergent ADAs00111000
Treatment-Induced ADAs00111000
Treatment-Boosted ADAs00000000
NAb Positive00000000
SecondaryPhase 2 (Safety Lead-In) Cohort B: Number of Participants With Anti-Drug Antibodies to Surzebiclimab

Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study in Cohort B: up to 21.5 months
Reported as:
Count of participants · Participants
Phase 2 (Safety Lead-In) Cohort B: Number of Participants With Anti-Drug Antibodies to Surzebiclimab
ParticipantsPhase 2 (Safety Lead-In): Cohort B: LBL-007 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Treatment-Emergent ADAs010
Treatment-Induced ADAs010
Treatment-Boosted ADAs000
NAb Positive ADAs000
SecondaryPhase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Surzebiclimab

Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Reported as:
Count of participants · Participants
Phase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Surzebiclimab
ParticipantsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Treatment-Emergent ADAs2401
Treatment-Induced ADAs2401
Treatment-Boosted ADAs0000
NAb Positive ADAs0100
SecondaryPhase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Alcestobart

Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Reported as:
Count of participants · Participants
Phase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Alcestobart
ParticipantsPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Treatment-Emergent ADAs200010
Treatment-Induced ADAs200010
Treatment-Boosted ADAs000000
NAb Positive ADAs001010
SecondaryPhase 2 (Dose Expansion) Cohorts 4 and 5: Number of Participants With Anti-Drug Antibodies to Alcestobart

Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Reported as:
Count of participants · Participants
Phase 2 (Dose Expansion) Cohorts 4 and 5: Number of Participants With Anti-Drug Antibodies to Alcestobart
ParticipantsPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Treatment-Emergent ADAs00
Treatment-Induced ADAs00
Treatment-Boosted ADAs00
NAb-Positive ADAs01
SecondaryPhase 1: Number of Participants With Anti-Drug Antibodies to Tislelizumab

Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: up to 57.5 months
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Anti-Drug Antibodies to Tislelizumab
ParticipantsPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab
Treatment-Emergent ADAs—0110120
Treatment-Induced ADAs—0110120
Treatment-Boosted ADAs—0000000
NAb Positive ADAs—0000000
SecondaryPhase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Tislelizumab

Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Reported as:
Count of participants · Participants
Phase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Tislelizumab
ParticipantsPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab
Treatment-Emergent ADAs310031
Treatment-Induced ADAs310021
Treatment-Boosted ADAs000010
NAb Positive ADAs100010
SecondaryPhase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Tislelizumab

Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.

Time frame:
Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Reported as:
Count of participants · Participants
Phase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Tislelizumab
ParticipantsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Treatment-Emergent ADAs71054
Treatment-Induced ADAs7944
Treatment-Boosted ADAs0110
NAb Positive ADAs0000
SecondaryPhase 2 (Dose Expansion): Number of Participants With TEAEs and SAEs

An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.

Time frame:
Up to 30 days after last dose of study drug (maximum treatment duration: Cohort 1: up to 6.9 months, Cohort 2: up to 23.5 months, Cohort 4: up to 9.6 months, Cohort 5: up to 15.4 months)
Reported as:
Count of participants · Participants
Phase 2 (Dose Expansion): Number of Participants With TEAEs and SAEs
ParticipantsPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
Any TEAE20212020
Grade 3 or above TEAE111199
Serious TEAE9869

Adverse events

Collected over All cause-mortality data was collected from randomization through end of study (up to 6 years 3 months). SAEs & nonserious AEs data: up to 30 days after last dose of study drugs (Maximum treatment duration: up to 32.7 months [Phase 1]; Cohort A: up to 19.6 months; Cohort B: up to 21.5 months [Phase 2 Safety Lead-In] and Cohort 1: up to 6.9 months, Cohort 2: up to 23.5 months, Cohort 4: up to 9.6 months, Cohort 5: up to 15.4 months [Phase 2 Dose Expansion]). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab1/1 (100%)1/1 (100%)1/1 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab1/1 (100%)1/1 (100%)1/1 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab0/3 (0%)3/3 (100%)3/3 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab1/5 (20%)2/5 (40%)4/5 (80%)
Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab2/4 (50%)2/4 (50%)4/4 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab1/7 (14.3%)1/7 (14.3%)7/7 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab1/3 (33.3%)0/3 (0%)3/3 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 60 mg1/1 (100%)1/1 (100%)1/1 (100%)
Phase 1 (Dose Escalation): Surzebiclimab 1600 mg0/1 (0%)1/1 (100%)1/1 (100%)
Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab2/4 (50%)3/4 (75%)4/4 (100%)
Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab3/6 (50%)3/6 (50%)6/6 (100%)
Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab2/6 (33.3%)4/6 (66.7%)6/6 (100%)
Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab3/6 (50%)4/6 (66.7%)4/6 (66.7%)
Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab4/6 (66.7%)3/6 (50%)6/6 (100%)
Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab15/21 (71.4%)9/21 (42.9%)20/21 (95.2%)
Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab11/22 (50%)8/22 (36.4%)20/22 (90.9%)
Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab11/20 (55%)6/20 (30%)20/20 (100%)
Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab8/20 (40%)9/20 (45%)20/20 (100%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
AnaemiaBlood and lymphatic system disorders0/10/10/30/50/70/40/70/31/10/10/40/60/60/31/60/60/210/220/200/20
Abdominal pain lowerGastrointestinal disorders0/10/10/30/50/70/40/70/31/10/10/40/60/60/30/60/60/210/220/200/20
Gastric perforationGastrointestinal disorders0/10/10/30/50/70/40/70/30/11/10/40/60/60/30/60/60/210/220/200/20
Small intestinal obstructionGastrointestinal disorders1/10/10/30/50/70/40/70/30/10/10/40/60/60/30/60/60/210/220/200/20
Bone painMusculoskeletal and connective tissue disorders0/11/10/30/50/70/40/70/30/10/10/40/60/60/30/60/60/210/220/200/20
Acute kidney injuryRenal and urinary disorders0/10/10/30/50/70/40/70/30/11/10/40/60/60/30/60/60/210/220/200/20
DyspnoeaRespiratory, thoracic and mediastinal disorders0/11/10/30/50/70/40/70/30/10/10/40/60/60/30/60/61/213/221/201/20
HypothyroidismEndocrine disorders0/10/10/30/50/70/40/70/30/10/10/40/60/61/30/60/60/210/220/200/20
Abdominal painGastrointestinal disorders0/10/11/31/50/70/40/70/30/10/10/40/60/60/30/60/60/210/220/200/20
DiarrhoeaGastrointestinal disorders0/10/11/30/50/70/40/70/30/10/10/40/60/60/30/60/60/210/220/200/20
Most frequent other events
Showing 10 of 298
Most frequent other events
EventPhase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab
AscitesGastrointestinal disorders1/10/10/30/50/70/40/70/30/10/10/40/60/60/30/60/60/210/220/200/20
ConstipationGastrointestinal disorders1/10/10/31/50/71/41/70/31/10/11/40/61/60/31/60/61/216/220/201/20
DiarrhoeaGastrointestinal disorders0/11/12/30/50/70/42/70/30/11/12/43/61/60/30/60/66/213/221/205/20
NauseaGastrointestinal disorders1/11/12/30/51/72/42/70/31/10/11/42/61/62/32/63/65/215/223/205/20
FatigueGeneral disorders and administration site conditions0/11/11/31/50/72/43/70/30/10/11/42/62/61/32/61/612/216/224/203/20
Oedema peripheralGeneral disorders and administration site conditions1/10/11/30/51/72/41/70/30/11/10/41/60/60/30/60/62/212/220/201/20
Alanine aminotransferase increasedInvestigations0/10/11/30/50/70/42/70/31/10/10/40/60/60/31/61/62/213/220/202/20
Aspartate aminotransferase increasedInvestigations0/10/10/30/50/70/42/70/31/10/10/40/60/60/31/61/62/213/221/202/20
Blood bilirubin increasedInvestigations0/10/10/30/50/70/41/70/31/10/11/40/60/60/30/60/60/210/221/200/20
HypomagnesaemiaMetabolism and nutrition disorders1/10/10/30/50/70/40/70/30/10/10/40/62/60/30/60/60/210/220/200/20

Baseline characteristics

Analysis was performed on Safety Analysis Set which included all participants who received at least 1 dose of study drug(s).

Age, Continuous
Age, Continuous(years)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabTotal
Mean66.066.053.3 ± 20.8460.6 ± 7.8062.9 ± 8.5758.8 ± 4.1958.7 ± 9.7945.3 ± 15.9547.056.061.0 ± 8.1665.3 ± 7.9963.0 ± 9.3261.3 ± 16.0761.5 ± 13.5065.5 ± 6.6660.9 ± 7.9164.5 ± 7.5264.2 ± 9.5765.4 ± 9.1862.4 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabTotal
Female1022643111332223287457
Male01131042001341431914131690
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabTotal
Hispanic or Latino000000000000100000315
Not Hispanic or Latino113474731145536521221717137
Unknown or Not Reported000100000001000100025
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1 (Dose Escalation): Surzebiclimab 2 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 6 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 20 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 200 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 400 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 800 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 1600 mg + TislelizumabPhase 1 (Dose Escalation): Surzebiclimab 60 mgPhase 1 (Dose Escalation): Surzebiclimab 1600 mgPhase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + TislelizumabPhase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + TislelizumabPhase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabPhase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + TislelizumabTotal
Asian00000100001001006142227
Black or African American000010000100000011307
White113563721035625514791398
More than one race000000000000001000012
Unknown000000000001000100215
Other000000010000000000001
Missing000000000000000000437
08

Study locations

40 sites
  • Chao Family Comprehensive Cancer Center
    Orange, California 92868-3201, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045-2517, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1443, United States
  • University of Kentucky Markey Cancer Center
    Lexington, Kentucky 40536-7001, United States
  • Weill Cornell Medical College Newyork Presbyterian Hospital
    New York, New York 10065-4870, United States
  • University of North Carolina At Chapel Hill
    Chapel Hill, North Carolina 27514-4220, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111-2434, United States
  • The University of Texas Md Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Ut Health San Antonio Mays Cancer Center
    San Antonio, Texas 78229-4427, United States
  • University of Virginia
    Charlottesville, Virginia 22908-0817, United States
  • Schar Cancer Institute
    Fairfax, Virginia 22031-4867, United States
  • Sydney Southwest Private Hospital
    Liverpool, New South Wales NSW 2170, Australia
  • Sunshine Coast Hospital and Health Service
    Birtinya, Queensland QLD 4575, Australia
  • Gold Coast University Hospital
    Southport, Queensland QLD 4215, Australia
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia SA 5112, Australia
  • Calvary North Adelaide Hospital
    North Adelaide, South Australia SA 5006, Australia
  • Box Hill Hospital
    Box Hill, Victoria VIC 3128, Australia
  • Cabrini Research and Education Institute
    Malvern, Victoria VIC 3144, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria VIC 3000, Australia
  • Western Health Sunshine Hospital
    St Albans, Victoria VIC 3021, Australia
  • Hollywood Private Hospital
    Nedlands, Western Australia WA 6009, Australia
  • Linear Clinical Research
    Nedlands, Western Australia WA 6009, Australia
  • Centre de Lutte Contre Le Cancer Institut Bergonie
    Bordeaux, 33000, France
  • Centre de Lutte Contre Le Cancer Francois Baclesse
    Caen, 14000, France
  • Institut Curie Paris
    Paris, 75005, France
  • Irccs Azienda Ospedaliero Universitaria Bologna
    Bologna, 40138, Italy
  • Fondazione Irccs Istituto Nazionale Dei Tumori
    Milan, 20133, Italy
  • Istituto Di Candiolo Irccs
    Torino, 10060, Italy
  • Chungbuk National University Hospital
    SeowonGu CheongjuSi, Chungcheongbukdo 28644, South Korea
  • The Catholic University of Korea, St Vincents Hospital
    PaldalGu SuwonSi, Gyeonggi-do 16247, South Korea
  • Gachon University Gil Medical Center
    NamdongGu, Incheon Gwang'Yeogsi 21565, South Korea
  • The Catholic University of Korea, Seoul St Marys Hospital
    SeochoGu, Seoul Teugbyeolsi 06591, South Korea
  • Severance Hospital Yonsei University Health System
    SeodaemunGu, Seoul Teugbyeolsi 03722, South Korea
  • Asan Medical Center
    SongpaGu, Seoul Teugbyeolsi 05505, South Korea
  • Ulsan University Hospital
    Donggu, Ulsan Gwang'Yeogsi 44033, South Korea
  • Ajou University Hospital
    Suwon, 16499, South Korea
  • Institut Catala Doncologia
    Barcelona, 08908, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Hm Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Feb 2025, 74 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 93 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 74 months is above that.

Counting every sponsor, half of 138 studies reached it within 61 months; a quarter within 47 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2018
First posted
Nov 16, 2018
StartActual
Nov 13, 2018
Primary completionActual
Feb 6, 2025
CompletionActual
Feb 6, 2025
Results first posted
Apr 2, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03744468
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 16, 2018
Start date
Nov 13, 2018
Primary completion
Feb 6, 2025
Completion
Feb 6, 2025
Results posted
Apr 2, 2026
Last update
Apr 2, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Alcestobart

Start the discussion